The MLL gene involved in llq23 translocations found in the majority of infantile leukemias and some secondary leukemias makes fusion transcripts with genes such as LTG4 (chromosome 4). LTG9 (chromosome 9). and LTGl9 (chromosome 19) as a result of reciprocal translocation. We have examined 25 cases of leukemias with 11q23 abnormalities by Southern blot analysis and the reverse transcriptasepolymerase chain reaction (RT-PCR). Using various primer pairs, chimeric mRNAs could be amplified in 6 of 7 leukemias with t(4; 1 I), 6 of 8 leukemias with t(9;ll) including second-EUKEMIAS WITH 1 lq23 translocation are clinically unique in being common in infants under 1 year of age and demonstrating biphenotypic or mixed-lineage features.'-4 Cytogenetically, more than 10 chromosomal loci have been found to be involved in 1 1 q23 translocations as partner chromosomes.s In infantile leukemias, t(4; 1 l)(q21;q23) and t( 11; 19)(q23;p13) are frequently observed, especially associated with acute lymphoblastic leukemia Acute leukemias with t(9; 1 l)(p22;q23) have monocytic features' and the same translocation is commonly reported to be also found in secondary leukemias linked to treatment with DNA topoisomerase I1 inhibitors, such as etoposide and teniposide."" Recently, genes involved in l lq23 translocations have been cloned and characterized. One of these, MLLi3." (variously named ALL-I,I5 HRX.'" or HTRXi7), encodes a 3,969 amino acid polypeptide homologous to Drosophila trithorax, containing two putative DNA-binding motifs consisting of three AT-hook motifs and two multiple zinc finger dornain~.'".'~~'~ Almost all the breakpoints in acute L
ary leukemia, 8 of 9 leukemias with t(ll;l9), and 1 with a deletion at 1 lq23. The chimeric mRNAs were heterogeneous and differential usage of the MLL exons was found, irrespective of the partner chromosomes. Sensitivity studies showed that a single clone with chimeric mRNA in lo' to 10' cells could be detected. These findings show that the present RT-PCR settings provide a rapid, accurate, and sensitive tool for diagnosing leukemias with 1 lq23 translocations and for monitoring response to therapy in these patients.
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leukemias with 1 lq23 translocations lie in a cluster region on the MLL By this translocation, two putative DNA-binding motifs are disrupted and the MLL gene is fused to genes on the partner chromosomes such as LTG4 (FELIAF-4)'s.23 LTG9 (AF-9),24. 25 or LTG19 (ENL),''." resulting in fused mRNA encoding chimeric proteins.
In this study, we analyzed the fusion points of 7 samples with t(4; 1 l), 8 samples with t(9;l I), 9 samples with t(1 I ; 19), and 1 sample with del(] l)(q23) leukemias by reverse transcriptase-polymerase chain reaction (RT-PCR). Amplifications are obtained in 21 of 25 leukemias with 1 Iq23 abnormalities, but the size of the PCR products is variable because of the heterogeneity of fusion sites of MLL and/or partner genes and alternative splicing. Furthermore, we designed a two round amplification for studying detection sensitivity for leukemias with I Iq23 translocations.
MATERIALS AND METHODS

Patient Samples and Cell Lines
Bone marrow or peripheral blood samples were obtained after informed consent of the patients or their parents. All patients' samples were fractionated on a Ficoll gradient and cryopreserved before use. Diagnosis of acute leukemia was made according to the FrenchAmerican-British (FAB) classification. Cytogenetic analysis was performed with standard methods. Table 1 summarizes general information for the samples and ceIl lines used in this study. Detailed characteristics of these cell lines have been previously reported?' The RS4; 1 1 cell line with the t(4; 1 l ) was obtained from the American Type Culture Collection (Rockville, MD). The cell lines were all cultured in RPMI-I640 medium supplemented with 10% fetal bovine serum. Patients no. 6, 7, and 8 had secondary leukemias after chemotherapy. Patient no. 6 was diagnosed as suffering from a malignant lymphoma, and a multidrug regimen including etoposide and doxorubicin was administered, with a total dose of 720 mg/ m' and 480 mg/m', respectively, and a secondary t(9; 1 1 ) leukemia developed 9 months after the initial diagnosis. Patient no. 7 was treated with a CHOP regimen for malignant lymphoma. A cumulative dose of 450 mg/m' of doxorubicin was administered and an acute monoblastic leukemia with t(9; 11) was found 14 months from the initiation of the treatment. Patient no. 8 had had small cell lung cancer and was treated with an etoposide-containing regimen. A cumulative dose of 9,700 mg/m2 of etoposide was administered Over 4 years, and patient no. 8 developed acute myelomonocytic leukemia with t(9; l 1 ). 
Blood
RNA Preparation and RT-PCR
Total RNA was prepared by the guanidium thiocyanate method as described ~reviously?~ Ten micrograms of total RNA was reverse transcribed to cDNA by incubation at 37°C for 1 hour in a total volume of 20 pL containing 0.6 pg of random hexamer, 500 pmoV L of each dNTP, 10 mmoVL dithiothreitol, 1 X RT buffer (50 mmoV U of Moloney murine leukemia virus reverse transcriptase (BRL, Bethesda, MD). At the end of the incubation, the reaction mixture was heated to 95°C for 5 minutes. For evaluation of sensitivity, total RNA of the leukemic cells was diluted at various concentrations in 10 pg of total RNA from an HL-60 cell line without any llq23 translocation and converted to cDNA as described above. For PCR amplification, 2 pL of the cDNA conversion mixture was used. The 2 pL mixture was increased up to 100 pL with IX PCR buffer (50 mmoVL KCI, 10 mmoliL Tris-HCI [pH 8.8 at 25"C], and 0.1% Triton-X-]M)), 1.5 mmoVL MgC12, 100 pm01 of each primer, 200 pmol/L of each dNTP, and 2.5 U of Taq polymerase (Promega, Madison, WI). Samples were overlaid with 100 pL of mineral oil (Sigma, St Louis, MO) and amplification was performed in a thermocycler. The reaction time consisted of an initial denaturation at 95°C for 2 minutes, annealing at 58°C or 62°C for 2 minutes, and elongation at 72°C for 10 minutes, followed by an additional 30 cycles (1 minute at 95"C, 2 minutes at 58°C or 62°C. Amplification with some primer pairs (MLLEx~S-LTG~AS, MLLEx5S-LTGgAS, and MLLEx6S-LTG19AS2) was performed in the presence of Perfect Match (Stratagene, La Jolla, CA) after the manufacturer's instructions. Briefly, 2 pL of cDNA conversion mixture was increased up to 98.5 pL with 1X PCR buffer, 1.5 mmoV L MgCI', 100 pmol of each primer, and 200 pmol/L of each dNTP. After denaturation at 95°C for 5 minutes and annealing at an appropriate temperature, 2.5 U of Taq polymerase, and 1 U of Perfect Match were added and 100 pL of mineral oil was overlaid, and then 30 cycles of amplification were performed with a program consisting, for each cycle, of 72°C for 1 minute, 95°C for 1 minute, and an appropriate annealing temperature for 2 minutes. At the end, an additional 10 minutes of extension was performed.
To assess the sensitivity of the RT-PCR, a two-round amplification protocol was applied (nested PCR). The first round of amplification was conducted at the fixed annealing temperature of 62°C and 35 cycles were performed. For the second round of PCR, 2-pL aliquots of first-round PCR product were used directly and 30 cycles of amplification were performed at the annealing temperature of 65°C.
One-tenth (10 pL) of the PCR product was electrophoresed in a 1.4% agarose gel. For cloning, 20 pL of PCR product was sizefractionated in a 1.0% low melting point gel and ligated into the pGEM-T vector (Promega). Primers used were as fol- 
Southern Blot Analysis
Southern blot analysis for MLL gene rearrangement was conducted as described previously.'" For evaluating sensitivity of the two-round amplification protocol, the PCR products were separated on 1.4% agarose gels, transferred onto nylon membranes (Hybond-N+; Amersham, Tokyo, Japan), and hybridized with an end-labeled oligonucleotide probe with 3' P using polynucleotide kinase. Autoradiography was performed with Kodak XAR-5 film (Eastman Kodak, Rochester, NY).
DNA Sequencing
Nucleotide sequences were determined by the dideoxy chain termination method using a 7-deaza Sequenase kit version 2.0 (US Biochemicals, Cleveland, OH). Some clones were deleted with a ExoIIIlMung bean nuclease deletion system according to the manufacturer's instructions (Stratagene) and sequenced.
Nucleotide Sequences of MLL, LTG4, LTG9, and LTG19
Nucleotide sequences and numbering of M U , LTG4, LTG9, and LTG19 are according to those in our previous reports ( M U , accesuse only. 
Nomenclature of the Genes Involved in lIq23 Translocations
The human genome nomenclature committee has suggested MLL as the name of the locus at 1 lq23, whereas those for loci at 4q21, 9p22, and 1 9~1 3 are MLLT2, MLLT3, and MLLTI, respectively. Various names being used regarding the genes involved in the 1 lq23 translocations by us and others are MLL, ALL-l, HRX, or HTRX for 1 lq23; LTG4, FEL, or AF4 for 4q21; LTG9 or AF-9 for 9~2 2 ; LTG19 or ENL for 19~13. We used our nomenclature, LTG (Leukemia nanslocation gene), plus chromosome number for translocation partner genes involved in the 1 lq23 translocation.
RESULTS
Southern Blot Analysis
All the cell lines and patients with an 1 lq23 abnormality showed MLL gene rearrangements at the 8.5-kb germline region detected by the MLL BamHI 0.9-kb cDNA probe (probe .)l9 where the breakpoints have been shown to cluster (Fig 1 and data not shown) .
A Strategy for RT-PCR Amplification of the Leukemias With I Iq23 Translocations
We and others have shown that the fusion points of M U transcripts in 1 lq23 translocations are at the 3' ends of exon 6, exon 7, or exon 8 of the MLL gene.'9.24.25s29 Because exon 5 is located at the 5' BamHI site of the germline 8.5-kb breakpoint clustering region, we set a sense oligonucleotide primer in the MLL exon 5 (MLLExSS), in addition to exon 6 (MLLEx6S) and exon 7 (MLLEx~S), so that even the most 5' breakpoint among the samples could be covered. Fusion points of LTG4, 9, and I9 to MLL have been reported to occur at two positions by ourselves and other g r o~p s '~~~'~~~ so that we set antisense primers downstream of each breakpoint for each gene (Fig 2D) .
RT-PCR and Sequence Analysis of Fusion Sites t(4; I I ) .
For the t(4; 1 l), two sets of primer pairs were used. With the MLLEx6S and LTG4ASI pair, 4 of 7 samples demonstrated amplification, whereas with the MLLEx6S and LTG4AS2 pair, 6 of 7 samples showed PCR products (Fig 2A) . The PCR product size was heterogeneous. By amplification with MLLEx6S and LTG4AS2, KOCL45 and KOCL-48 lines showed a 495-bp product, whereas the KOCL-69 line and patient no. 2 showed a 609-bp product. The RS4; 11 line gave a 627-bp and patient no. 1 gave 696-and 582-bp products. This heterogeneity was further studied by nucleotide sequencing. In KOCL-45 and KOCL-48, the end of MLL exon 6 was fused to nucleotide number 1414 of LTG4 (site A). In the RS4; 11 line, the MLL exon 7 and the LTG4 fusion site A were fused. Patient no. 1 showed two chimeric mRNAs, the shorter one using M U exon 7 and the longer one using MLL exon 8. Both were fused to the same position at nucleotide number 1459 of LTG4 (site B), indicating that the two chimeric mRNAs were generated by alternative splicing at the MLL gene. KOCL-69 uses MLL exon 8 and it fuses to nucleotide number 1546 of LTG4, a more 3' site to LTG4 fusion site B (site C). Thus, the heterogeneity of chimeric mRNA for the t(4; 11) translocation is due to differential exon usage of the MLL and LTC4 genes and alternative splicing. KOCL-58 showed no amplification with either of these primer pairs or with MLLEx5S and LTG4 antisense primers located on the more 3' side, with intervals of about 650 bp to cover the entire coding region (data not shown). t(9; 11). For t(9; 1 l), we previously reported a fusion site of LTG9 in IMS-M1 (site A)25 and Nakamura et a124 showed the same fusion site in addition to a more 3' fusion site (site B). We designed three antisense primers for the LTG9; LTG9ASl and 2 fit between the two fusion sites A and B, whereas LTG9AS3 is more 3' to the LTG9 fusion site B (Fig 2D) . In the IMS-M1 cell line, PCR products with two different sizes of 577 bp and 463 bp were obtained with the MLLEx6S and LTG9AS2 primer pair. Sequencing of these products showed the longer one to be the result of fusion between MLL exon 8 and LTG9 fusion site A and the shorter one of fusion between MLL exon 7 and LTG9 fusion site A, indicating that the two chimeric products are generated by alternative splicing at the M U gene. An identical pattern to IMS-M1 was shown by the KOPB-26 line as well as by patients no. 3, 6, and 8. A 331-bp product was obtained in patient no. 4 and sequence analysis showed that this product was generated by fusion between MLL exon 6 and LTG9 fusion site A. Because patients no. 5 and 7 did not show any PCR products with this primer pair, we next attempted to amplify these two patients' samples with a set of MLLEx5S and LTG9AS3 using KOPB-26 as a positive control. In KOPB-26, the expected sizes of 815-bp and 701-bp PCR products were obtained, but no products were amplified in the two patients. Moreover, although we performed PCR of the two patients' samples using LTG9 antisense primer located on more 3' side, no amplification was obtained (data not shown).
t(1I; 19).
With regard to t(l1; 19), we previously reported that fusion between the MLL and LTG19 genes occurs at three sites of the MLL gene; exons 6, 7, and 8; and two sites of the LTGI9 gene, site A and B.I9 We have investigated 4 cell lines and 5 patients' samples. Using MLLEx6S and LTG19AS2, a 419-bp PCR product was detected in KOCL-33, which was generated by fusing MLL exon 7 to LTGI9 fusion site A. An identical pattern was obtained for KOCL-50. With the same primer pair, KOCL-44, and patients no. 11, 12, and 13 showed PCR products with two different sizes, generated by fusion of either MLL exon 7 or 8 to LTGI9 site A, indicating alternative splicing at the MLL gene. The longer 533-bp product was generated by fusion of MLL exon 8 to the LTGI9 fusion site A and the shorter 419-bp one (the same size as that of KOCL-33) by fusion of MLL exon 7. This pattern was detected most frequently, in 4 of 8 samples of t(l1; 19). Interestingly, the del(l1 )(q23) cell line, KOCL-51, showed the same pattern. Patient no. 9 showed a 287-bp PCR product with this primer pair and sequencing analysis showed that fusion had occurred between MLL exon 6 and the LTG19 fusion site A. With these use only. v . RT-PCR analysis of MLL-LTG4, MLL-LTG9, and MLL-LTGlS fusion transcripts of cell lines and patients with llq23 abnormalities. Total RNA was prepared from samples with t(4;ll)(A), t(9;ll)(B), t(11;19) and del(ll)(q23)(C), and RT-PCR was conducted using the primer pairs indicated below each panel. A diagrammatic presentation of the primer setting is shown (D). The patient numbers correspond to those listed in Table 1 . HL-60 is a leukemic cell line without any llq23 abnormality. The 383-bp fragment detected using MLLEx7S and MLLex9AS shown below is a control for RNA integrity. The sizes of the amplified products are indicated on the right side. The size markers of +X/Haelll are indicated by dashes on the left side (1357,1078,872,603,310,281 and 271,234,194, and l18 bp). In (D), for MLL and LTG4, parts of the genes are shown, and for LTG9 and LTG19, boxes and lines indicate the entire coding regions and noncoding regions, respectively. Arrows indicate fusion sites that are described in detail in the text. Parenthesized number below each primer is the nucleotide number of its 5' end. For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From of HL-60 without any llq23 translocation and then converted to cDNA. As shown in Fig 3 , PCR products were detected in ethidium-stained gel at up to a 10-5-fold dilution for t(4; 11) and t(9; 1 l), and for t(l1; 19). Southern hybridization analysis showed positive signals at the same dilutions (data not shown).
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DISCUSSION
PCR analysis has proved useful for diagnosis and detection of minimal residual disease in various hematopoietic malignancie~~'.~~ and the recent cloning of the genes involved in 1 lq23 translocations provide us with the information necessary for development of RT-PCR for rapid and sensitive diagnosis and monitoring of patients with this translocation. Among regions in more than 10 chromosomes involved as translocation partners: 4q21, 9p22, and 1 9~1 3 have been most frequently noted and the responsible genes were recently cloned by ourselves and others.'6.'8.'9,23-25. 43 Because the breakpoints at 1 lq23 in all 25 cases examined in this study were found to cluster at the 8.5-kb germline region detected by BamHI 0.9-kb MLL cDNA by Southern blot analysis, we designed primers for MLL so as to be able to cover the chimeric transcript of der (1 1). Previous reports also suggested heterogeneous fusion points at genes on partner chromosomes.L9~23~24 Therefore, we introduced various antisense primers so that chimeric transcripts could be detected. In t(4; l l ) cases, using the same sense primer MLLEx~S, 6 of 7 showed chimeric products with LTG4AS2, whereas two of those positive cases were not detectable with LTG4AS 1, indicating the importance of primer selection for the amplification (Fig 2A) . In 8 of 9 t( 11; 19) cases, products could be amplified, and 1 case of these needed more 3' antisense primer (Fig 2C) . With regard to t(9; 1 l), 6 of 8 cases were amplified, and 2 negative cases did not show amplification using the antisense primer located 3' to the breakpoint recently reported by Nakamura et al." Sequence analysis of the chimeric products demonstrated preferential exon usage in LTG9 and LTGl9, but more heterogeneity was found in LTG4. Our present data showing that 21 of 25 cases could be amplified indicate that RT-PCR for 1 lq23 is of clinical use.
The KOCL-51 cell line was shown to have del(1 l)(q23) by conventional cytogenetic analysis, but RT-PCR analysis indicated that it contains an MLL-LTG19 transcript, ie, t(l1; 19). As shown by Kobayashi et al,44 using fluorescence in situ hybridization, llq23 deletions are almost always caused by undetected translocations. That may be also the case for the KOCL-51 line.
Clinically, leukemias with MLL gene rearrangements have been reported to demonstrate a poor pr0gnosis.4~ For such patients, detection of minimal residual disease is important for monitoring response to therapy and also for predicting latent relapse. Because the sensitivity of the RT-PCR was found to be 1 of lo4 to IO5 by our primer setting, the present approach has promise in the clinical setting. To evaluate the correlation between positivity in the RT-PCR assay and prognosis, prospective studies will be needed with application of chemotherapy and bone marrow transplantation. The RT-PCR outlined here should provide an accurate and sensitive analytical tool for patients with llq23 translocations.
We could not amplify chimeric products in 4 of 25 cases. Because all the cases were shown to have breakpoints in the clustering region and the primers at M U were made to cover all the breakpoints, it is likely that the lack of amplification was caused by the antisense primers. One possibility is that a different gene on the same region of the translocation partner was involved. Such a possibility has been demonstrated for 1 9~1 3 by Mitani et a1,& who found heterogeneity for the 19p13 breakpoint by in situ hybridization. Because the translocation partner chromosomes are more than 10 in number: the MLL gene at 1 lq23 may not require very specific genes to gain leukemogenicity. Indeed, the predicted amino acid sequence of LTG4 ( E L ) is not homologous to either that of LTG19 (ENL) or that of LTG9 (AF-9).23-25 A common characteristic for these partner gene products is, however, present, ie, they are serine/proline rich. Recent characterization of a t(X; 11) also demonstrated that AFXl on chromosome X is rich in ~erine/proline.~~ In any case, it is of interest to characterize the cases that were. not amplified to clarify the genes on the partner chromosomes. This should facilitate elucidation of the mechanisms underlying leukemogenesis involving the MLL gene.
